Organisation paid for research Program year 2022 Source: CMS Open Payments

US Renal Care Inc

Neither a doctor nor a teaching hospital

Research payments

$1,703,829

1,184 payments

Through program year 2022, US Renal Care Inc is reported as receiving $1,703,829 in research payments, across 1,184 payments.

By program year

4 rows
Year Kind Amount Payments
2022 Research $3,256 3
2021 Research $19,506 8
2020 Research $610,159 90
2019 Research $1,070,909 1,083

Breakdown

Who paid Research payments · program years 2019–2022
  1. Akebia Therapeutics Inc $1,674,397 1,173 payments
  2. GlaxoSmithKline, LLC. $19,986 6 payments
  3. Grifols, S.A. $8,846 4 payments
  4. Ardelyx, Inc. $600 1 payment
Studies the money was for Research payments · program years 2019–2022
  1. Akb-6548-Ci-0017 $989,310 1,013 payments
  2. Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (Dd-Ckd) (Inno2vate-Conversion) $577,926 76 payments
  3. Akb-6548-Ci-0014 $49,622 36 payments
  4. Akb-6548-Ci-0015 $31,977 34 payments
  5. A Phase 3 Randomized, Open-Label (Sponsor-Blind), Active-Controlled, P $19,986 6 payments
  6. Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Conversion) $9,502 5 payments
  7. Akb-6548-Ci-0014 $7,976 3 payments
  8. A Randomized, Double-Blind, Phase 2a Study to Evaluate the Tolerability, Feasibility, and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment Associated With End-Stage Renal Disease $6,190 2 payments
  9. Akb-6548-Ci-0015 $5,340 3 payments
  10. Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Correction) $2,745 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record